



The European Agency for the Evaluation of Medicinal Products
Evaluation of Medicines for Human Use

London, 4 May 2001
CPMP/1262/01 corr.

PRESS RELEASE

Committee for Proprietary Medicinal Products 24-25 April 2001 meeting

The CPMP adopted two opinions on initial marketing authorisation applications at this meeting:

- Positive opinion for Eli Lilly's Liprolog* (insulin lispro) indicated for the treatment of diabetes mellitus (*Liprolog, Liprolog-Pen, Liprolog Mix25, Liprolog Mix50, Liprolog Mix25 Pen and Liprolog Mix50 Pen).
- Negative opinion for Snow Brand France's Evoxac (cevimeline) indicated for the treatment of symptoms of dry mouth in patients with primary Sjögren's syndrome or with secondary Sjögren's syndrome associated with rheumatoid arthritis, polymyositis, systemic lupus erythematosus or systemic sclerosis.

Summaries of these opinions are available on the EMEA web site.

As part of the Committee's ongoing scientific review on cardiovascular risks on third generation oral contraceptives, the CPMP heard an oral explanation from marketing authorisation holders. The CPMP will continue its discussions at its next meeting on 29 to 31 May 2001.

Other actions taken by the CPMP include establishment of an ad hoc Expert Group on Paediatrics under Dr Daniel Brasseur, chairman of the CPMP.

A more detailed CPMP meeting report will be made available next week, including details from the MRFG meeting of 23 April 2001.

--ENDS--

For further information please contact:

Noël Wathion
Head of Unit, Post-authorisation evaluation of medicinal products
Tel. (44-20) 7418 8592